Clinical trials: Diabetic Retinal Disease
Nonproliferative Diabetic Retinopathy
Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)
The primary objective of the study is to assess the efficacy of intravitreal (IVT) aflibercept compared to sham treatment in the improvement of moderately severe to severe nonproliferative diabetic retinopathy (NPDR).
- Trial name
- PANORAMA (NCT02718326)
- Testing
- Intravitreal aflibercept injection [IAI]
- Where
- 89 sites in United States, Germany and 4 more
- Volunteers
- 402 people
- Sponsor
- Regeneron Pharmaceuticals
Diabetic Macular Edema
Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
The purpose of this study was to evaluate the efficacy and safety of brolucizumab vs. aflibercept in the treatment of patients with visual impairment due to diabetic macular edema (DME).
- Trial name
- KINGFISHER (NCT03917472)
- Testing
- Brolucizumab, Aflibercept
- Where
- 92 sites in United States, Hungary and 3 more
- Volunteers
- 517 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Retinopathy
Pivotal Trial to Assess the Clinical Performance of Ophthal-360 for the Detection of Diabetic Retinopathy
Multicenter, prospective, study to assess the performance of the Ophthal-360 platform in the diagnosis of more-than-mild Diabetic Retinopathy (mtmDR) in diabetic patients with no previous diagnosis of DR.
- Trial name
- NCT05806957
- Testing
- Fundus Photography
- Volunteers
- 500 people
- Sponsor
- Ophthalytics, Inc.
Diabetes Mellitus, Diabetic Retinopathy
Combined Effects of Diabetes Self-Management Education and Nutritional Supplementation on Visual Function and Retinopathy
The purpose of this study is to evaluate the combined effects of diabetes self-management education (DSME) and nutritional supplementation on visual function and retinopathy incidence \& progression in patients with type 1…
- Trial name
- NCT04120077
- Testing
- EyePromise DVS, EyePromise DVS plus EyePromise EZTears
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- ZeaVision, LLC
Macular Edema
A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applicator in Adult Participants With Macular Edema Due to Diseases of the Retina
The Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator is used to deliver an implant with medicine to the eye. AbbVie is updating the DEX PS DDS Applicator.
- Trial name
- NCT04976777
- Testing
- Updated DEX PS DDS Applicator, Approved DEX PS DDS Applicator, Dexamethasone
- Where
- 7 sites in United States
- Volunteers
- 54 people
- Sponsor
- AbbVie
Diabetic Retinopathy (DR), Diabete Mellitus
Clinical Efficacy of Implementing an AI-SaMD for Funduscopy Analysis in Patients With Diabetes Mellitus
The objective of this study is to investigate the efficacy of implementing the AI-SaMD(VUNO Med®-Fundus AI™) alongside routine clinical practice for the detection of diabetic retinopathy.
- Conditions
- Diabetic Retinopathy (DR), Diabete Mellitus, Fundus Photography
- Trial name
- SAFE-DM (NCT07378956)
- Testing
- VUNO Med®-Fundus AI™
- Where
- South Korea
- Volunteers
- 340 people
- Sponsor
- VUNO Inc.
Non-Proliferative Diabetic Retinopathy, Retinal Vein Occlusion
Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Diabetic Retinopathy or Retinal Vein Occlusion
The goal of this clinical trial is to learn about the safety of the investigational medicinal product ANXV. It will also learn about how ANXV works to treat non-proliferative diabetic retinopathy and retinal vein occlusion in…
- Trial name
- NEXUS (NCT07259928)
- Testing
- ANXV
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Annexin Pharmaceuticals AB
Neovascular Age-related Macular Degeneration (NVAMD), Diabetic Macular Edema (DME)
A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)
EYE103-101 is a 2-part study assessing safety and preliminary efficacy of EYE103 in patients with diabetic macular edema (DME) given as monotherapy or neovascular macular degeneration (NVAMD) given in combination with anti-VEGF.
- Trial name
- AMARONE (NCT05919693)
- Testing
- EYE103
- Where
- 32 sites in United States, Argentina and 2 more
- Volunteers
- 33 people
- Sponsor
- EyeBiotech Ltd.
Diabetic Macular Edema, Visual Impairment
A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese Diabetic Macular Edema (DME) Patients
Study of efficacy and safety of 0.5 mg ranibizumab in Chinese patients with diabetic macular edema (DME)
- Trial name
- REFINE (NCT02259088)
- Testing
- Ranibizumab (RFB002), Laser
- Where
- 28 sites in China
- Volunteers
- 384 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Retinopathy
Nesvategrast (OTT166) in Diabetic Retinopathy (DR)
This study will evaluate the safety and efficacy of OTT166 Ophthalmic solution in participants with Diabetic Retinopathy.
- Trial name
- NCT05409235
- Testing
- OTT166, Vehicle control
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 225 people
- Sponsor
- OcuTerra Therapeutics, Inc.
Macular Edema
A Safety and Efficacy Study of Dexamethasone Versus Laser Photocoagulation in Participants With Diabetic Macular Edema
This study will evaluate the safety and efficacy of 700 μg dexamethasone versus laser photocoagulation in participants with diabetic macular edema (DME).
- Trial name
- NCT02121262
- Testing
- Dexamethasone, Laser Photocoagulation
- Where
- 18 sites in China, Philippines
- Volunteers
- 284 people
- Sponsor
- Allergan
Diabetic Macular Edema (DME)
A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular Edema
The purpose of this study is to learn about the effects of BGE-102 on change in vision in participants with center-involved diabetic macular edema (CI-DME).
- Trial name
- QUELL-DME (NCT07812090)
- Testing
- Oral BGE-102, Anti-VEGF
- Where
- 16 sites in United States
- Volunteers
- 180 people
- Sponsor
- BioAge Labs, Inc.
Non-proliferative Diabetic Retinopathy
Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy
Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects with Moderately Severe to Severe Non-proliferative Diabetic Retinopathy
- Trial name
- NCT05695417
- Testing
- OTX-TKI
- Where
- 10 sites in United States
- Volunteers
- 21 people
- Sponsor
- Ocular Therapeutix, Inc.
Diabetes Mellitus, Diabetic Retinopathy
A Study to Evaluate the Safety of THR-149 in Subjects With Diabetic Macular Edema (DME)
This study is conducted to evaluate the safety of a single intravitreal injection of THR-149.
- Conditions
- Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema
- Trial name
- NCT03511898
- Testing
- THR-149 dose level 1, THR-149 dose level 2, THR-149 dose level 3
- Where
- 7 sites in United States
- Volunteers
- 12 people
- Sponsor
- ThromboGenics
Diabetic Retinopathy
Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula Edema
The purpose of this study was to demonstrate that the change of best corrected visual acuity (BCVA) was comparable in patients treated with ranibizumab at the discretion of the investigator vs.
- Trial name
- DIVERSE (NCT02366468)
- Testing
- ranibizumab 0.5 mg
- Where
- 30 sites in Germany
- Volunteers
- 135 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Retinopathy
Extension Study of Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy
This multicenter, open-label extension study will evaluate the long-term tolerability and safety for patients completing study CSMS995 0802.
- Trial name
- NCT00248131
- Testing
- Octreotide acetate in microspheres
- Volunteers
- 260 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Retinopathy, HIV
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
To show the non-inferiority of EGRIFTA® vs. placebo in the development or progression of Diabetic Retinopathy in HIV-infected subjects with concomitant abdominal lipohypertrophy and Type 2 diabetes mellitus (T2DM).
- Trial name
- NCT01591902
- Testing
- Tesamorelin
- Where
- 24 sites in United States
- Volunteers
- 129 people
- Sponsor
- Theratechnologies
Diabetic Retinopathy, Diabetic Eye Problems
Validation Study of RETINA-AI Galaxy™, an Automated Diabetic Retinopathy Screening Device
Diabetes affects approximately 35 million Americans, each of whom needs at least one retinal exam per year. However, majority do not get their eye exam due to multiple prohibitive factors such as cost, transportation, difficulty…
- Conditions
- Diabetic Retinopathy, Diabetic Eye Problems, Diabetic Macular Edema
- Trial name
- NCT04774822
- Testing
- Color Fundus Photography, Mydriatics Agent, Optical Coherence Tomography (OCT)
- Where
- 3 sites in United States
- Volunteers
- 397 people
- Sponsor
- RETINA-AI Health, Inc.
Center-involved Diabetic Macular Edema (CI-DME)
Prospective Study of Adjunctive Carotenoids Plus Anti-oxidants in Anti-VEGF Treated Diabetic Macular Edema
This study will evaluate the effects of add-on carotenoid plus anti-oxidant nutritional supplementation to standard anti-vascular endothelial growth factor therapy for subjects with center-involved diabetic macular edema
- Trial name
- PROACTIVEDME (NCT03866005)
- Testing
- Diabetes Visual Function Study (DiVFuSS) softgels
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- ZeaVision, LLC
Diabetic Macular Edema
A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)
This is a randomized, masked, active-controlled, parallel-group, multi-center study that will assess the efficacy of ILUVIEN as a baseline therapy in the treatment of Center Involving DME (CI-DME).
- Trial name
- NEW DAY (NCT04469595)
- Testing
- Iluvien 0.19 MG Drug Implant, Aflibercept
- Where
- 40 sites in United States
- Volunteers
- 300 people
- Sponsor
- Alimera Sciences